# Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma

> **NCT07394244** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 38 (estimated)

## Conditions studied

- Cutaneous Squamous Cell Carcinoma (CSCC)

## Interventions

- **DRUG:** Pucotenlimab
- **DRUG:** Becotatug Vedotin

## Key facts

- **NCT ID:** NCT07394244
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-09
- **Primary completion:** 2028-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2026-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07394244

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07394244, "Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07394244. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*